A randomized, placebo-and active-controlled trial of bazedoxifene/ conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

Menopause

Volumn 17, Issue 2, 2010, Pages 281-289

  Kagan, Risa ^a   Williams, R Stan ^b   Pan, Kaijie ^c   Mirkin, Sebastian ^c   Pickar, James H ^c  

^a Foundation for Osteoporosis Research and Education   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c PFIZER INC   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Postmenopausal; Tissue selective estrogen complex; Vulvar vaginal atrophy

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL; BODY WEIGHT; CELL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; FEMALE; HEADACHE; HUMAN; INFECTION; INJURY; INSOMNIA; LEG CRAMP; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSE; MIGRAINE; MULTICENTER STUDY; MYALGIA; NAUSEA; OVARY CYST; PAIN; PARABASAL CELL; PATIENT SATISFACTION; PH; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCREENING; SEXUAL BEHAVIOR; SIDE EFFECT; SUPERFICIAL CELL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS; VAGINITIS; VASODILATATION;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ATROPHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

EID: 77949370016     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181b7c65f     Document Type: Article

References (22)

1. Bachmann GA, Cheng RJ, Rovner E. Vulvovaginal complaints. In: Lobo RA, ed. Treatment of the Postmenopausal Woman. Burlington, MA: Academic Press, 2007:263-269.
2. Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct 2001;12:107-110.
3. Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996;24:31-36.
4. Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/ medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-276.
5. Raymundo N, Yu-Cheng B, Zi-Yan H, et al. Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 2004;7:312-318.
6. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.
7. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060.
8. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358.
9. Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet Gynecol Scand 2005;84:72-78.
10. Cumming GP, Herald J, Moncur R, Currie H, Lee AJ. Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a Web-based survey. Menopause Int 2007;13:79-83.
11. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181:71-79.
12. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial protection in menopausal therapy with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens. Fertil Steril 2009;92: 1018-1024.
13. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
14. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmeno-pausal women. Fertil Steril 2009;92:1045-1052.
15. Food and Drug Administration. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy SymptomsVRecommendations for Clinical Evaluation. Bethesda MD: US Department of Health and Human Services 2003, 1-10.
16. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40.
17. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
18. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life Questionnaire and development of a modified version, MENQOL-Intervention Questionnaire. Maturitas 2005;50:209-221.
19. Hill CD, Fehnel SE, Bobula JD, Yu H, McLeod LD. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047-1055.
20. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009. Epub ahead of print June 10, 2009.
21. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-1044.
22. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885-889.